Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BSTC BioSpecifics Technologies	$88.53	$88.47	$42.00 ▼ $89.15	$650.25M	0.24	61,105 shs	N/A
CBAY CymaBay Therapeutics	$32.48	$32.09	$7.26 ▼ $32.50	$3.73B	0.32	4.11 million shs	73 shs
EOLS Evolus	$11.56 -0.7%	$13.67	$7.07 ▼ $15.43	$669.79M	1.45	629,337 shs	341,706 shs
FLXN Flexion Therapeutics	$9.12	$9.20	$4.30 ▼ $13.66	$458.93M	1.53	1.18 million shs	N/A
OBSV ObsEva	$0.01	$0.03	$0.08 ▼ $2.14	$390K	0.68	8.94 million shs	66,910 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BSTC BioSpecifics Technologies	0.00%	0.00%	0.00%	0.00%	0.00%
CBAY CymaBay Therapeutics	0.00%	0.00%	+0.06%	+36.64%	+230.08%
EOLS Evolus	-3.40%	-8.85%	-16.86%	-1.69%	+42.65%
FLXN Flexion Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
OBSV ObsEva	+1,150.00%	+150.00%	-66.67%	-85.71%	-94.32%

Biden’s $374B Giveaway Into This Sector (Ad)

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BSTC BioSpecifics Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CBAY CymaBay Therapeutics	0.8924 of 5 stars	2.0	0.0	0.0	4.7	0.0	2.5	0.6
EOLS Evolus	4.1622 of 5 stars	3.5	3.0	0.0	3.5	3.2	2.5	0.6
FLXN Flexion Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OBSV ObsEva	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BSTC BioSpecifics Technologies	N/A	N/A	N/A	N/A
CBAY CymaBay Therapeutics	2.08	Hold	$28.65	-11.79% Downside
EOLS Evolus	3.00	Buy	$20.60	78.20% Upside
FLXN Flexion Therapeutics	N/A	N/A	N/A	N/A
OBSV ObsEva	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest OBSV, EOLS, CBAY, FLXN, and BSTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/10/2024	EOLS Evolus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
3/1/2024	EOLS Evolus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
2/29/2024	CBAY CymaBay Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$32.50
2/20/2024	CBAY CymaBay Therapeutics	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$32.50
2/14/2024	CBAY CymaBay Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
2/14/2024	CBAY CymaBay Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$33.00 ➝ $32.50
2/14/2024	CBAY CymaBay Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$25.00 ➝ $32.50
2/13/2024	CBAY CymaBay Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
2/13/2024	CBAY CymaBay Therapeutics	Jonestrading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
2/13/2024	CBAY CymaBay Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$32.50
2/13/2024	CBAY CymaBay Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$29.00 ➝ $32.50

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BSTC BioSpecifics Technologies	$38.19M	17.03	$3.38 per share	26.18	$18.42 per share	4.81
CBAY CymaBay Therapeutics	$31.07M	119.92	N/A	N/A	$2.58 per share	12.59
EOLS Evolus	$202.09M	3.31	N/A	N/A	($0.36) per share	-32.11
FLXN Flexion Therapeutics	$85.55M	5.36	N/A	N/A	($0.34) per share	-26.82
OBSV ObsEva	$20.11M	0.02	N/A	N/A	$0.41 per share	0.01

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BSTC BioSpecifics Technologies	$24.47M	$3.33	37.51	17.60	N/A	47.43%	14.81%	14.46%	N/A
CBAY CymaBay Therapeutics	-$105.37M	-$0.97	N/A	N/A	N/A	N/A	-50.72%	-31.04%	5/20/2024 (Estimated)
EOLS Evolus	-$61.69M	-$1.09	N/A	N/A	N/A	-30.52%	N/A	-32.19%	5/14/2024 (Estimated)
FLXN Flexion Therapeutics	-$113.71M	-$2.01	N/A	N/A	N/A	-100.32%	N/A	-44.26%	N/A
OBSV ObsEva	-$58.38M	-$0.92	N/A	∞	N/A	N/A	-416.36%	-92.01%	N/A

Latest OBSV, EOLS, CBAY, FLXN, and BSTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/7/2024	Q4 2023	EOLS Evolus	-$0.15	-$0.20	-$0.05	-$0.19	$61.14 million	$61.00 million
2/28/2024	Q4 2023	CBAY CymaBay Therapeutics	-$0.31	-$0.35	-$0.04	-$0.35	$0.42 million	$0.06 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BSTC BioSpecifics Technologies	N/A	N/A	N/A	N/A	N/A
CBAY CymaBay Therapeutics	N/A	N/A	N/A	N/A	N/A
EOLS Evolus	N/A	N/A	N/A	N/A	N/A
FLXN Flexion Therapeutics	N/A	N/A	N/A	N/A	N/A
OBSV ObsEva	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BSTC BioSpecifics Technologies	N/A	66.24	66.24
CBAY CymaBay Therapeutics	N/A	10.96	10.96
EOLS Evolus	N/A	2.33	2.10
FLXN Flexion Therapeutics	N/A	4.38	4.05
OBSV ObsEva	N/A	0.61	0.61

Ownership

Institutional Ownership

Company	Institutional Ownership
BSTC BioSpecifics Technologies	60.34%
CBAY CymaBay Therapeutics	95.03%
EOLS Evolus	90.69%
FLXN Flexion Therapeutics	90.01%
OBSV ObsEva	17.52%

Insider Ownership

Company	Insider Ownership
BSTC BioSpecifics Technologies	15.70%
CBAY CymaBay Therapeutics	7.00%
EOLS Evolus	5.40%
FLXN Flexion Therapeutics	9.13%
OBSV ObsEva	14.40%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BSTC BioSpecifics Technologies	7	7.35 million	N/A	Not Optionable
CBAY CymaBay Therapeutics	101	114.72 million	106.69 million	Optionable
EOLS Evolus	273	57.94 million	54.82 million	Optionable
FLXN Flexion Therapeutics	257	50.32 million	45.73 million	Optionable
OBSV ObsEva	48	77.97 million	66.74 million	Not Optionable

OBSV, EOLS, CBAY, FLXN, and BSTC Headlines

Source	Headline
	ObsEva (NASDAQ:OBSV) Coverage Initiated by Analysts at StockNews.com americanbankingnews.com - April 12 at 2:16 AM
	ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listin globenewswire.com - April 3 at 1:00 AM
	ObsEva Announces Update on Board of Directors globenewswire.com - March 19 at 2:00 AM
	ObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023 globenewswire.com - February 28 at 1:00 AM
	ObsEva Stock (OTC:OBSEF) Dividends: History, Yield and Dates benzinga.com - February 26 at 12:34 AM
	ObsEva SA OBSN morningstar.com - November 11 at 10:37 PM
	ObsEva SA OBSEF morningstar.com - November 11 at 7:36 AM
	ObsEva (NASDAQ: OBSV) fool.com - June 18 at 11:34 PM
	Tocolytic Agents Market to a Steady Revenue CAGR of 5.3% by ... - InvestorsObserver news.google.com - May 10 at 1:37 AM
	ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - Yahoo Finance news.google.com - May 2 at 1:32 PM
	ObsEva Says Fabien De Ladonchamps Is New CEO - Nasdaq news.google.com - May 2 at 8:31 AM
	ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - GlobeNewswire news.google.com - May 2 at 1:20 AM
	Gameto Appoints Teri Loxam as Chief Financial Officer - citybiz news.google.com - April 28 at 11:20 PM
	ObsEva Annual Report 2022 - Marketscreener.com news.google.com - April 28 at 6:20 PM
	ObsEva Annual Report 2022 - Yahoo Finance news.google.com - April 28 at 6:20 PM
	ObsEva Annual Report 2022 - Benzinga news.google.com - April 28 at 1:20 PM
	ObsEva Annual Report 2022 - EIN News news.google.com - April 28 at 1:20 PM
	Gameto Expands Executive Team with the Addition of Teri Loxam as ... - PR Newswire news.google.com - April 28 at 8:19 AM
	Endometriosis Market to Hit USD 3.9 Bn by 2029: Competitive ... - Digital Journal news.google.com - April 26 at 6:27 PM
	Endometriosis Pain Pipeline Insight, Emerging Therapies, Key Players, and Clinical Stages - openPR news.google.com - April 23 at 8:45 PM
	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq - Marketscreener.com news.google.com - April 21 at 3:44 PM
	ObsEva Announces Change of Central Securities Depositary - Yahoo Finance news.google.com - April 20 at 11:41 PM
	ObsEva Announces Change of Central Securities Depositary - GlobeNewswire news.google.com - April 20 at 1:10 AM
	Tackling Reproductive Health and Fertility Care - Pharmaceutical Executive news.google.com - April 13 at 6:41 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

BioSpecifics Technologies

NASDAQ:BSTC

BioSpecifics Technologies Corp., a biopharmaceutical company, develops an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX and Xiapex brands. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma, and uterine fibroids. The company has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Wilmington, Delaware.

CymaBay Therapeutics

NASDAQ:CBAY

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

Evolus

NASDAQ:EOLS

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Flexion Therapeutics

NASDAQ:FLXN

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

ObsEva

NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial